6,7-Diethoxy-2,4-dichlor-chinazolin | 20197-81-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6,7-Diethoxy-2,4-dichlor-chinazolin
• 英文别名: 2,4-dichloro-6,7-diethoxy-quinazoline；2,4-Dichloro-6,7-diethoxyquinazoline
• CAS: 20197-81-3
• 化学式: C₁₂H₁₂Cl₂N₂O₂
• mdl: MFCD23100295
• 分子量: 287.145
• InChiKey: WVCHDLJGCKUCNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  44.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• QUINAZOLINE DERIVATIVE
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0726267A1

  公开（公告）日：1996-08-14

  Disclosed are quinazoline derivatives represented by formula (I): wherein R1 represents hydrogen, lower alkyl, alkenyl, or aralkyl; R2, R3, R4, and R5 represent hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, or the like; R6, R7, R8, and R9 represent hydrogen, lower alkyl, lower alkoxy, aralkyloxy, or the like, or any adjoining two of them are combined to form methylenedioxy or the like; R10 represents hydrogen, lower alkyl, or the like; R11 and R12 represent hydrogen, lower alkyl, cycloalkyl, phenyl, or aralkyl, or R11 and R12 are combined together with N to form a heterocyclic group; and n represents 0, 1 or 2, and pharmaceutically acceptable salts thereof. These compounds have adenosine uptake inhibitory activity and are useful for the protection of myocardium and for the prevention or treatment of inflammation such as leg and foot edema.

  公开了式 (I) 所代表的喹唑啉衍生物： 其中 R1 代表氢、低级烷基、烯基或芳基；R2、R3、R4 和 R5 代表氢、低级烷基、低级烷氧基、低级烷酰基或类似物；R6、R7、R8 和 R9 代表氢、低级烷基、低级烷氧基、芳基氧基或类似物，或其中任意相邻的两个结合形成亚甲基二氧基或类似物；R10 代表氢、低级烷基或类似物；R11 和 R12 代表氢、低级烷基、环烷基、苯基或芳烷基，或 R11 和 R12 与 N 结合形成杂环基团；n 代表 0、1 或 2、 及其药学上可接受的盐类。 这些化合物具有腺苷摄取抑制活性，可用于保护心肌和预防或治疗炎症，如腿部和足部水肿。
• THERAPEUTIC AGENT FOR KIDNEY DISEASES
  申请人：KYOWA HAKKO KOGYO KABUSHIKI KAISHA

  公开号：EP0919233A1

  公开（公告）日：1999-06-02

  Disclosed is a therapeutic agent for renal disease comprising a quinazoline derivative represented by formula (I): (wherein R1 represents hydrogen, lower alkyl, alkenyl, or aralkyl; R2, R3, R4, and R5 are the same or different and represent hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, or the like; R6, R7, R8, and R9 are the same or different and represent hydrogen, lower alkyl, lower alkoxy, aralkyloxy, or lower alkanoyloxy, or the like, or any adjoining two of them are combined to form methylenedioxy or the like; R10 represents hydrogen, lower alkyl, or the like; R11 and R12 are the same or different and represent hydrogen, lower alkyl, cycloalkyl, phenyl, or aralkyl, or R11 and R12 are combined together to form a heterocyclic group containing nitrogen atom; and n represents 0, 1 or 2) and pharmaceutically acceptable salts thereof as an active ingredient. This therapeutic agent is useful for the prevention or treatment of renal diseases such as nephritis and diabetic nephropathy.

  本发明公开了一种治疗肾病的药物，该药物包含由式（I）代表的喹唑啉衍生物： (其中R1代表氢、低级烷基、烯基或芳烷基；R2、R3、R4和R5相同或不同，代表氢、低级烷基、低级烷氧基、低级烷酰基或类似物；R6、R7、R8和R9相同或不同，代表氢、低级烷基、低级烷氧基、芳烷氧基或低级烷酰氧基或类似物，或其中任意相邻的两个结合成亚甲基二氧基或类似物；R10 代表氢、低级烷基或类似物；R11 和 R12 相同或不同，代表氢、低级烷基、环烷基、苯基或芳烷基，或 R11 和 R12 结合在一起形成含氮原子的杂环基团；n 代表 0、1 或 2）及其药学上可接受的盐类作为活性成分。 这种治疗剂可用于预防或治疗肾炎和糖尿病肾病等肾脏疾病。
• QUINAZOLINE DERIVATIVES
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0726267B1

  公开（公告）日：2000-11-22
• US5948784A
  申请人：——

  公开号：US5948784A

  公开（公告）日：1999-09-07